Kancera has completed patient recruitment for the COVID-19 study with KAND567

by | Jun 16, 2021

Kancera AB (Nasdaq First North Premier Growth Market: KAN) announces that the recruitment of patients for the exploratory phase IIa study with KAND567 has ended after just over 80 percent of the originally planned number of COVID-19 patients have received their dose....

Kancera announces that an application for a clinical phase IIa study with KAND567 after heart attack has been submitted to the UK Medicines Agency (MHRA)

by | May 24, 2021

Kancera AB (Nasdaq First North Premier Growth Market: KAN) announces today that the application for permission to start a phase IIa study evaluating the safety and cardioprotective effect of KAND567 in heart attack patients has been submitted to the UK Medicines and...

Interim report for first quarter 2021, 1 January – 31 March 2021

by | May 21, 2021

First quarter in briefNet sales for the period (January to March) amounted to SEK 0 million (SEK 0 million).R&D costs for the period amounted to SEK 8,2 million (SEK 9,7 million).Operating profit for the period amounted to SEK -9,0 million (SEK -11,1...

Kancera provides update on successful phase I study and planned phase II study with KAND567 treatment following heart attack

by | Jan 15, 2021

This is a translation of a press release in Swedish published December 29, 2020 Kancera AB (Nasdaq First North Premier Growth Market: KAN) announces today that the company's new capsule product with KAND567 has been evaluated in a successful phase I study in...

Kancera appoints a Scientific Advisory Board with leading scientists in cardiology and immunology

by | Jan 15, 2021

This is a translation of a press release in Swedish published December 21, 2020 Kancera AB (Nasdaq First North Premier Growth Market: KAN) announces that the company has established a Scientific Advisory Board consisting of three leading scientists in the fields of...